Depth of response and progression status at last follow-up
| Best response . | All patients . | |||
|---|---|---|---|---|
| VGPR/CR n = 113 . | PR n = 14 . | SD/PD n = 17 . | P value . | |
| Median ALCmax, ×103/μL (IQR) | 1.5 (0.8-3.1) | 0.8 (0.5-1.3) | 0.5 (0.4-0.7) | <.001 |
| Progression status | Nonprogressor n = 88 | Progressor n = 68 | P value | |
| Median ALCmax, ×103/μL (IQR) | 1.82 (0.92-4.27) | 0.79 (0.49-1.40) | <.001 | |
| Best response . | All patients . | |||
|---|---|---|---|---|
| VGPR/CR n = 113 . | PR n = 14 . | SD/PD n = 17 . | P value . | |
| Median ALCmax, ×103/μL (IQR) | 1.5 (0.8-3.1) | 0.8 (0.5-1.3) | 0.5 (0.4-0.7) | <.001 |
| Progression status | Nonprogressor n = 88 | Progressor n = 68 | P value | |
| Median ALCmax, ×103/μL (IQR) | 1.82 (0.92-4.27) | 0.79 (0.49-1.40) | <.001 | |
Only patients with >3 months of follow-up were included in the best response assessment. Response and progression based on International Myeloma Working Group criteria.